Delcath Q2 2023 Earnings Report
Key Takeaways
Delcath Systems reported total revenue of $0.5 million for the second quarter ended June 30, 2023, compared to $0.8 million for the prior year period. The company's research and development expenses were $3.6 million, compared to $5.6 million in the prior year quarter. Selling, general and administrative expenses for the quarter increased to $4.8 million, compared to $4.5 million in the prior year quarter.
Continued communication with the FDA regarding the HEPZATO KITâ„¢ NDA resubmission, with an anticipated PDUFA date of August 14, 2023.
Stockholders approved the potential issuance of common stock upon conversion of preferred stock from a private placement, generating $25 million on closing with potential for up to an additional $60 million upon warrant exercises and revenue milestones.
Hired Vojislav Vukovic, MD, PhD as Chief Medical Officer, Sandra Pennell as Senior Vice President of Finance, and Zac MacLean as Director of Sales and Strategy.
Continued to treat patients at 3 Expanded Access Program sites.
Delcath
Delcath
Forward Guidance
The Company has been preparing for the commercialization of HEPZATO KIT, if approved.